Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My Cart

Main menu

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Clinical and Vaccine Immunology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Archive
  • About the Journal
    • About CVI
    • For Librarians
    • For Advertisers
    • FAQ
Spotlight

Articles of Significant Interest Selected from This Issue by the Editors

DOI: 10.1128/CVI.00231-16
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Novel Respiratory Syncytial Virus-Like Particle Vaccine

Respiratory syncytial virus (RSV) is the leading cause of severe respiratory disease in infants globally. Cimica et al. (p. 451–459) developed a novel RSV-like particle (RSV VLP) vaccine assembled with human metapneumovirus (hMPV) matrix protein as the structural scaffold and RSV fusion glycoprotein (F) as the main immunogen in postfusion, prefusion, or postfusion-plus-prefusion conformation. Immunization with alternative RSV VLP vaccine formulations afforded full protection and was safe in the mouse model of RSV disease; however, the RSV VLP vaccine composition combining postfusion and prefusion F elicited the highest level of neutralizing antibody and stimulated a greater Th1-mediated immune response.

Figure1
  • Open in new tab
  • Download powerpoint

A combination RSV VLP vaccine containing prefusion and postfusion conformations of F induces the highest level of neutralizing antibodies.

Heptameric Staphylococcus aureus Alpha-Hemolysin and Immune Responses

To evaluate the structural, functional, and immunogenic characteristics of both monomeric and heptameric Staphylococcus aureus alpha-hemolysin (Hla), Fiaschi et al. (p. 442–450) engineered and detoxified the pore-forming toxin by removing the membrane-spanning stem domain. The monomer of this mutated protein, HlaPSGS, forms heptamers in aqueous solution and resembles the cap of the wild-type cytolytic Hla pore. Antibody responses against S. aureus, both in humans and in mice, were found directed primarily against epitopes present only in the heptameric Hla toxin. These are important observations for the understanding of the immunology of S. aureus infections as well as for developing innovative vaccines.

Figure2
  • Open in new tab
  • Download powerpoint

Typical HlaPSGS class averages showing the seven identical protomers (A) and top (i) and side (ii) surface views of the HlaPSGS electron density map (B).

  • Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PreviousNext
Back to top
Download PDF
Citation Tools
Articles of Significant Interest Selected from This Issue by the Editors
Clinical and Vaccine Immunology Jun 2016, 23 (6) 437; DOI: 10.1128/CVI.00231-16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Email

Thank you for sharing this Clinical and Vaccine Immunology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Articles of Significant Interest Selected from This Issue by the Editors
(Your Name) has forwarded a page to you from Clinical and Vaccine Immunology
(Your Name) thought you would be interested in this article in Clinical and Vaccine Immunology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Articles of Significant Interest Selected from This Issue by the Editors
Clinical and Vaccine Immunology Jun 2016, 23 (6) 437; DOI: 10.1128/CVI.00231-16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • Novel Respiratory Syncytial Virus-Like Particle Vaccine
    • Heptameric Staphylococcus aureus Alpha-Hemolysin and Immune Responses
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About CVI
  • For Librarians
  • For Advertisers
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • Submit a Manuscript to mSphere

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 1556-6811; Online ISSN: 1556-679X